Yazan Madanat is an Oncology physician affiliated with Southwestern Medical Center. OpenAlex indexes 379 publications with 1,598 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2201 Inwood Rd # Nc2.130
Dallas, TX 752357320
Telephone
214-645-4673Registry record last updated 10 Jun 2019.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments
- Geron CorporationProgram year20255 payments
- Blueprint Medicines CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
21.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.2%Acyclovir100%Part D≥73 patientsCancer & immunology
20.1%Kinase inhibitor6.9%Jakafi100%Part D≥13 patientsIsocitrate Dehydrogenase 2 Inhibitor2.9%Idhifa100%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
19.8%Bile Acid5.1%Ursodiol100%Part D≥18 patientsProton pump inhibitor5%Pantoprazole Sodium100%Part D≥20 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology
2025 - NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Claus Roehrborn, MD
Southwestern Medical Center
Trish Perl, MD
Southwestern Medical Center
Lisa Vanwagner, MD
Southwestern Medical Center
Jose Joglar, MD
Southwestern Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”